Ultomiris for generalised myasthenia gravis
The first and only long-acting C5 inhibitor, Ultomiris (ravulizumab), has been permitted in Europe with generalised myasthenia gravis.
Marc Dunoyer European Commission Committee For Medicinal Products Human Use With Ultomiris Medicinal Products Human Use
Source: europeanpharmaceuticalreview.com